Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512668 · ClinicalTrials.gov registry record · Phase 1
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00512668: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00512668 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512668, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by lowering the amount of androgens the body makes. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hormone therapy together with temsirolimus may kill more tumor cells
Interventions
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG bicalutamide
- DRUG flutamide
- DRUG nilutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512668
The ClinicalTrials.gov registry entry for NCT00512668 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00512668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512668 about?
NCT00512668 is a clinical study titled "Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer". This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by lowering the amount of andr...
What is the current status of trial NCT00512668?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-09.
What interventions are being tested in trial NCT00512668?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin acetate (DRUG), bicalutamide (DRUG), flutamide (DRUG), nilutamide (DRUG).
Who is sponsoring clinical trial NCT00512668?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.